Syna Therapeutics signs global deal on biosimilar LB-0702

2 November 2022

Four years after it was established, Syna Therapeutics has just signed an exclusive license agreement with Indian drugmaker Intas Pharmaceuticals and its wholly-owned subsidiary Accord Healthcare for the marketing worldwide of its biosimilar medicine LB-0702 to treat pathologies in the field of hematology.

Set up in 2018, Syna Therapeutics is a joint venture owned by LeanBio and Spain’s Reig Jofre (BME: RJF), for the development of biopharmaceutical products in the field of biosimilars and innovative molecules.

According to the terms of the agreement, Syna Therapeutics will begin in 2023 the clinical trials for its biosimilar LB-07802. For its part, Intas, will cover the marketing costs. Intas currently has one of the largest sales, marketing, and distribution networks for biosimilars in the world, particularly to hospitals, with a presence in 85 countries.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK